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Background: Human Immunodeficiency Virus (HIV) viral load and CD4+ cell counts are the most commonly used 
markers for monitoring efficacy of anti-retroviral therapy (ART) in HIV infected individuals. The high cost of viral 
load monitoring limits its usage in resource limited countries, often leaving the use of CD4+ T cell counts as the only 
alternative. Though cheaper and more readily available, CD4+ cell counts as a measure of detecting treatment failure, 
is an unreliable predictor of disease progression. Hence, there is a need for more sensitive alternative, but less costly 
techniques for detecting treatment failure which can be used in resource limited settings.  
Objective: To evaluate the feasibility of using plasma CD26/Dipeptidyl peptidase IV (DPPIV) as a novel marker for 
clinical evaluation of treatment efficacy in HIV infected children. 
Method:  Blood samples collected from HIV+ children (n=76) before and after initiation on ART, were assessed for 
HIV RNA (viral load), CD4+ T-cell count and DPPIV/CD26 levels. Viral load levels were analyzed using Roche Amplicor 
HIV-1 Monitor Test kit; CD4+ T-Cell Counts were analyzed using BD FACS Calibur flow cytometer while DPPIV/CD 
26 levels were analyzed using Human DPPIV/CD26 Quantikine ELISA kit (R&D Systems, Minneapolis MN).  
Results: The plasma DPPIV/CD26 levels increased significantly in children after ART initiation (p = 0.017), while the 
viral load levels declined after ART initiation with subsequent CD4+ cell counts increase. The DPPIV/CD 26 increase 
positively correlated with viral load decrease while negatively correlating to the CD4+ cell count increase.  
Conclusion: These findings demonstrate an inverse relationship between DPPIV/CD26 levels and HIV viral load and 
the direct proportionality of CD4+ Cell counts and DPPIV/CD26 levels, suggesting potential for use of DPPIV/CD26 
as a surrogate marker for evaluating HIV disease progression in children receiving anti-retroviral therapy. 
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1. Introduction 
Since its emergence, HIV/AIDS has remained as one of 
the worst scourges to afflict humanity. (Gottlieb et al, 
1981; Barré-Sinoussi et al, 1983; Schüpbach et al, 1985; 
Gallo, 2006).  By the end of 2014, WHO estimated the 
number of people living with HIV/AIDS at 36.3 (35.3-39) 
million people globally, and the number of those who had 
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died from AIDS related illness since 1981 at 39 million 
(UNAIDS report, 2013). The development of anti-
retroviral (ARV) drugs has been one of the most 
significant milestones in the battle against HIV/AIDS, 
and has largely been responsible for significant 
reduction in morbidity and mortality among infected 
individuals. In recent years, the numbers of annual AIDS-
related deaths have decreased from a global peak of 2.1 
million in 2004, to an estimated 1.2 million in 2014 
(UNAIDS, 2015). This has been largely attributed to 
increased availability and coverage of ART, care and 
support of people living with HIV/AIDS (UNAIDS, 2013).  
Antiretroviral drugs (ARVs) are classified depending on 
the stage of the virus life cycle they target, with most of 
the drugs categorized based on their enzymatic targets 
(Wainberg and Jeang, 2008).  The first class of ARVs to be 
developed, targeted the viral enzyme reverse 
transcriptase, and subsequently new drugs targeting 
viral protease, integrase and HIV fusion proteins have 
been developed, increasing the treatment options 
(Reeves and Piefer, 2006). The increased use of 
combination ART, has drastically improved the efficacy 
of ART leading to reductions in both morbidity and 
mortality, and increasing life expectancy of HIV infected 
individuals. The use of efficacious ART is lifelong and the 
benefits conferred by its usage have turned HIV/AIDS 
from a death sentence to a chronic and manageable 
infection (Brenner et al, 2007; Murphy et al, 2001). The 
treatment options available, have also improved over the 
years with the development of newer, less toxic, longer-
acting and more effective compounds capable of better 
suppression of viral replication (Wainberg and Jeang, 
2008). 
The effectiveness of anti-retroviral therapy in HIV 
infected individuals is often determined by routine 
monitoring and evaluation of virologic and immunologic 
parameters such as HIV viral load and CD4+ T cell counts, 
respectively. Viral load monitoring involves the 
quantification of HIV RNA in the plasma, usually; 
effective ART results in undetectable levels of HIV-RNA 
in plasma or below 50 copies/ml (Reeves and Piefer, 
2006). CD4+ T cell counts monitoring is a measure of the 
number of CD4+ T cells present in the blood of an HIV 
infected individual. In 2015, WHO adjusted its 
recommendations for ART initiation, calling for all 
individuals found to be HIV positive irrespective of CD4+ 
T cell count to be put on ART (WHO, 2015; Jain et al, 
2013; Vernazza et al, 2000).The recommendations also 
include the provision of ARVs to children under the age 
of 10 years. Any child aged 10 years or more should be 
put on ART if their CD4 count is below 500 cells/µl 
(WHO, 2015).  
The use of viral load and CD4+ T cell counts for 
monitoring ART efficacy among HIV infected individuals 
has its limitations (Paintsil, 2011). The frequent and 
reliable use of viral load testing in resource-rich 
countries complements the quality of care given to HIV 
infected persons. However, it usage in resource-limited 
countries is low in frequency or completely absent, and 
where it is present the sensitivity and reliability is 
questionable (UNAIDS, 2013). Viral load quantification 
requires expensive equipment with high maintenance 
costs, highly skilled operators, costly reagents and 
specialized laboratory infrastructure, which are often 
not present in low-income countries (Katzenstein et al, 
2003). Despite the recent introduction of relatively 
cheaper viral load testing techniques like the ExaVir load 
in some resource-limited countries (Cairns, 2009)  the 
costs of viral load assays remain prohibitive in most low-
income countries (Nkengasong et al, 2009). Viral load 
testing despite being expensive is a more reliable 
predictor of disease progression and treatment failure as 
compared to CD4+ T cells count (Hogg et al, 2001). CD4+ 
T cell counts is more readily available in such settings, 
but lacks the sensitivity needed for  early detection of 
treatment failure, due to the slower rate of decline in 
CD4+ T-cells counts (up to months) following treatment 
failure (Paintsil, 2011). 
There are also situations of discordant virology and 
immunologic responses, where there is a persistently 
low or declining CD4+ T cell counts in spite of complete 
virologic suppression, or a rising CD4+ T-cell count with 
increasing or high viral load (Gazzola et al, 2009).  
Despite these challenges of viral load monitoring in 
resource limited countries, its usefulness in 
complementing CD4+ cell counts for optimal ART 
outcomes is widely accepted (Wang et al,2010). There is 
therefore a need to develop simpler, more robust, low 
maintenance and cost-effective laboratory techniques to 
monitor the clinical efficacy of ARV therapy in these 
resource-limited countries (Janossy et al, 2008).   
Previously, it has been shown that blood DPPIV/CD26 
levels could inversely correlate to HIV viral load, and 
directly correlate with CD4+ T cell levels in adult infected 
persons (Ohtsuki et al, 2001). This supported the 
premise that increased expression of DPPIV may be 
immunologically relevant to the course of HIV disease 
(Wrenger et al, 1997; Dong and Morimoto, 1996). 
Additionally, a study conducted in commercial sex 
workers (CSWs) from Kenya, found a higher expression 
of the enzyme Dipeptidyl peptidase IV/CD26 in the 
peripheral blood of HIV exposed seronegative Female 
Sex Workers (FSW) (Songok et al, 2010). These findings 
suggest that, higher DPPIV/CD26 levels may have a 
protective role against HIV acquisition among females’ 
commercial sex workers in Kenya. CD26 is a 110 kDa 
protein that has dipeptidyl peptidase IV activity which 
cleaves N-terminal dipeptides after proline or alanine 
residues leading to the release of a number of 
chemokines that have this terminal sequence (Ohtsuki et 
al, 2001; Havre et al, 2008; Cordero et al, 2009; Iwaki-
Egawa et al, 1998). Soluble DPPIV or sCD26 is 
enzymatically active in biological fluids including 
peripheral blood (Havre et al, 2008; Cordero et al, 2009; 
Iwaki-Egawa et al, 1998).  
In this study, we determined the relationship between 
the plasma levels of DPPIV/CD26, HIV viral load and 
CD4+ T cell counts in HIV infected individuals, as a means 
of evaluating the potential for use of DPPIV/ CD26 levels 
as a surrogate marker for HIV disease progression in 
children receiving ART. 
2. Methodology 
2.1 Study Site 
This study was conducted in a group of children enrolled 
in the Lea Toto programme, an initiative of the Children 
of God Relief Institute (COGRI) that provides home based 
HIV care services to infected children and their families 
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in the low income areas of Nairobi, Kenya. The sampling 
was done at the various Lea Toto Centres namely: 
Kawangware, Kibera, Dagoretti, Mukuru, Kariobangi, 
Zimmerman, Dandora and Kangemi. The laboratory 
procedures were later carried out at the Nyumbani 
Diagnostic Laboratory located at the Nyumbani 
Children’s Home and the Kenya Medical Research 
Institute (KEMRI). 
2.2 Study design and study population 
The study design was a comparative before and after 
study. 
The study participants were all HIV positive children 
receiving care services under the Lea Toto programme at 
the Lea Toto Centres located in the mentioned low 
income areas of Nairobi. A total of 76 HIV positive 
children between the ages of 1 year to 20 years from all 
the Lea Toto centres in Nairobi were recruited randomly 
in this study using simple random sampling method. 
2.3 Care Services provided under the Lea Toto 
Programme 
Children accepted into the Lea Toto programme, 
undergo a clinical evaluation of their blood for HIV viral 
load and CD4+ T cell counts, which are routinely 
monitored to determine when ART can be initiated. The 
children are also offered routine prophylaxis and 
treatment for opportunistic infections. The nutritional 
status is also closely monitored, and parents or care-
givers are advised on a balanced diet. 
During the period of study, the Kenyan ART guideline for 
children was that all children below 10 years old, ART is 
started automatically regardless of the CD 4+ cell counts 
but for children above 10 years old, ART is started once 
the CD4+ T cell counts go below 500 cells per mm3.  
The choice of ART was Nucleoside Reverse Transcriptase 
Inhibitors (NRTIs) combination chosen was either 
AZT/3TC or ABC/3TC, but TDF/3TC could be used for 
older children or adolescents; the Non-Nucleoside 
Reverse Transcriptase Inhibitors (NNTRI) selected 
depended on exposure to NVP during pregnancy; those 
exposed were to be put on a Protease inhibitor (PI) 
namely LPV/r; for those not NVP-exposed, either NVP or 
EFV was to be used according to the age and/or weight 
of the child.  
2.4 Sample collection and preparation  
The first sample was collected before ART initiation and 
second sample collected an average of 7.2 months after 
ART initiation. A total of 152 samples were collected.  
Five ml of whole blood was collected from the median 
cubital vein in K3-EDTA vacutainers tubes (BD, Franklin 
Lakes, New Jersey), and transported within an hour to 
the laboratory on ice packs. CD4+ T-cell counts 
determination was done and the remaining blood was 
separated by centrifuging at 1500 rpm for 7 minutes.  
The plasma was used for HIV viral load quantification 
then refrigerated at -80O C for a month and later used for 
soluble DPPIV/CD26 quantification.  
2.5 DPPIV/CD26 quantification by ELISA.  
Soluble DPPIV/CD26 plasma levels, was quantified using 
Human DPPIV/CD26 Quantikine ELISA kit (R&D 
Systems, Minneapolis MN) according to the 
manufacturer’s recommendations. DPPIV/CD26 capture 
antibodies were coated onto flat bottomed 96 well plates 
and incubated overnight at room temperature. Following 
the overnight incubation, the plates were washed three 
times using a wash buffer (included in kit), and then 
blocked using 300μl of 1% Bovine Serum Antigen (BSA) 
reagent diluent (Life Technologies-Thermo Fisher 
Scientific, USA)  added to each well followed by a 1 hour 
incubation. 100μl of samples, standards or controls, 
were then added to the respective wells in duplicate and 
incubated for two hours at room temperature. The 
standards were added serially by diluting from a top 
concentration of 2000pg/ml to a lowest concentration of 
15.625pg/ml. The plasma samples were diluted using 
10% BSA reagent in a volume/volume ratio of 1:1000. 
After the incubation, the plates were washed thrice using 
wash buffer, and detection antibody at a concentration of 
36 ng/ml, was then added to each well.  The plates were 
then incubated for two hours at room temperature, and 
subsequently washed thrice using the wash buffer, and 
100μl of the Streptavidin-HRP enzyme conjugate was 
then added to each well followed by twenty minute 
incubation at room temperature in the dark. Following 
the incubation, the plates were washed thrice, and a 
substrate made from TMB (3, 3’, 5, 5;-
tetramethylbenzidine) solution in hydrogen peroxide 
was added to each well, then incubated for twenty 
minutes at room temperature away from direct light. 
Following this incubation, 50μl of the stop solution was 
then added to each well, and plates read immediately at 
450 nm with a correction wavelength of 540 or 570 nm 
on a MULTISCAN EX ELISA Reader (Thermo Scientific, 
Massachusetts, USA). 
The optical densities (ODs) of standards were used to 
generate a standard curve, which was in turn used for the 
determination of the sample concentrations. 
Subsequently, the sample concentrations were then 
multiplied by 1000 (the plasma dilution factor) and 
normalized by subtracting the ODs of the negative 
controls (reagent diluent only).  
2.6 Viral load quantification 
HIV-1 RNA or viral load quantification in blood plasma 
was performed by RT-PCR using Roche Amplicor HIV-1 
Monitor Test kit that is fully automated. In brief, plasma 
specimens were treated using guanidine thiocyanate or 
ultracentrifuged for low-level quantitation. Plasma 
specimens or HIV-1 quantitation standards (QS) with 
known RNA copy numbers,  were first reverse 
transcribed into cDNA using RT-PCR, then quantified by 
RT- PCR. After the reverse transcription of the HIV-1 and 
QS target RNA, the reaction mixture was heated to 
denature the RNA:cDNA hybrid and expose the HIV-1 
and QS target sequences. The sequences were then 
amplified to create an amplicon 142 base pairs long in 
the area of the HIV-1 genome between the primers.  After 
PCR reaction, the HIV-1 and QS amplicons were 
chemically denatured to form a single stranded DNA by 
the addition of a denaturation solution and aliquots 
added into separate wells of a micro-plate coated with 
HIV specific and QS-specific oligonucleotide probes. 
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Later, the substrate (Horse radish peroxidase-avidin 
conjugate) was added to the probes detected by 3,3’,5,5’-
tetramethylbenzidine (TMB). An automated micro-well 
plate reader was used in reading the optical densities 
(OD) after the reaction was stopped by the addition of a 
weak acid. The amount of HIV-1 RNA in the sample was 
calculated using a ratio of the optical densities of the total 
HIV-1 RNA and the total HIV-1 QS RNA optical density 
and the input number of QS RNA copies that was 
incorporated into each individual patient sample at 
known copy numbers during the specimen preparation. 
The input number of QS RNA is lot- specific and is 
entered by the user before the reaction. In addition to the 
quantitative standards, three additional controls 
accompanied the kit, these were; the negative; low-
positive and high-positive tested in each assay run 
provided with the kit. The kit does not specify the exact 
identity of the controls. 
2.7 CD4+ T-cell counts quantification 
The quantification of the CD4+ T cell counts was also 
done using a FACS Calibur cytometer (BD). 20 μL of BD 
Tritest CD4/CD8/CD3 reagent was added to each BD 
Trucount tube above the stainless steel retainer without 
disturbing the pellet. 50 μL of well-mixed anticoagulated 
whole blood was then pipetted into each tube, without 
smearing the blood onto the sides of the tube, for 
enhanced accuracy of CD4+ T cell count quantification.  
Each tube was then capped and mixed gently by 
vortexing, then incubated for 15 minutes in the dark at 
room temperature. 450 μL of 1x BD FACS lysing solution 
was then added to each tube, capped and gently vortexed 
to mix. The tubes were then incubated for 15 minutes in 
the dark, and subsequently the cells were suspended and 
analyzed on the flow cytometer. The flow data was 
acquired using the BD Multiset software, with the 
threshold adjusted prior to data acquisition to minimize 
background noise and to ensure that populations of 
interest were included in the data acquisition. Data 
analysis was done using BD Multiset software, which was 
also used for calculating the absolute number of CD4+ T 
cell cells/μL per sample.  
2.8 Data Analysis 
Data analysis was performed using the Graphpad Prism 
version 5.0. Comparison of general DPPIV/CD26, viral 
loads and CD4+ T cell counts before and after initiation 
of ART, was done using paired t-tests. Correlational 
analysis of DPPIV/CD26 levels with viral load and CD4+ 
T cell counts was conducted using Spearman’s 
correlation coefficient. Categorized data comparison for 
males and females before and after ART was done using 
paired t-tests while the general differences between 
male and female children was done using Mann-Whitney 
test statistics.  Data categorized into different age groups 
before and after ART was analyzed using paired t tests 
while general differences between the age groups were 
compared using Mann-Whitney test statistics. All p-value 
below 0.05 was considered to be statistically significant 
and reported. 
2.9 Ethical considerations 
Ethical approval for this study was obtained from the 
Kenya Medical Research Institute Ethics committee SSC 
(Scientific steering Committee) approval number 2344 
and permission for use of samples was provided by the 
Children of God Relief Institute (COGRI) - The umbrella 
body which governs the Lea Toto programme and the 
Nyumbani Children’s home. Informed consent was 
provided by parents, guardians or grown up children 
capable of giving consent-under the age of 18 but can 
comprehend and understand the benefits and risks of the 
research. 
3.  Results  
This study included 76 children- 34 (44.7%) male and 42 
(55.3%) female-with equal distribution of sexes. The 
average ages per sex were, 7.53 and 7.81 for male and 
female, respectively, with a cumulative average age of 7.8 
years for both sexes. Fourteen children were below 2 
years, with equal number of males and female, 32 of the 
children were aged 3-9 (13 female and 19 male) and 30 
were adolescents aged between 10-20 (16 females and 
14  males) . The distribution of the children sampled 
from the eight  Lea Toto programme centres was as 
follows; 13 from Kawangware (8 females and 5 males), 9 
from Kibera (5 males and 4 females),  3 from Mukuru (2 
females and 1 male), 4 from Dandora (all  male), 14 from 
Kangemi (7 females and 7 males), 7 from Zimmerman (6 
females and 1 male), 3 from Dagoretti (2 females and 1 
male) and finally 23 were from Kariobangi (14 females 
and 9 males). 
HIV infected children had DPPIV/CD26 levels 
corresponding to CD4+ T cell counts but inversely 
correlating to HIV viral loads 
First we sought to establish the levels of DPPIV/CD26, 
previously shown to positively correlate with CD4+ T cell 
counts, and negatively with HIV viral load in children. 
Moreover, DPPIV/CD26 levels have been associated with 
improved outcomes in HIV infected individuals and 
reduced susceptibility to HIV in HESN female CSWs in 
Nairobi (16, 17).We hypothesized that DPPIV/CD26 
plasma levels would be directly proportional with levels 
of CD4 T cells but inversely to viral loads. To test this, we 
quantified the levels of soluble DPPIV/CD26, HIV viral 
load in the plasma, and CD4+ T cells counts from the 
whole blood of HIV infected children. We observed that, 
the average levels of DPPIV/CD26 in the blood of 
children (n=76) before initiation of ART was 
830800±438000 pg/ml which significantly rose after 
initiation of ART to 972800±606200 pg/ml (p=0.0017) 
(Figure 1a). The average viral load in HIV infected 
children declined from 164600 ± 177170 copies/ml 
before ART initiation to 31960 ± 8497 copies per Ml 
(p<0.0001) after ART initiation. The average CD4+ Cell 
counts was 663.9 ± 598.8  cells per mm3 which increased 
significantly after ART initiation to 963.8 ± 930.2 cells 
per mm3 (IQR-402) (p<0.0001) (Figure 1b) . 
Next we compared the relationship between increases in 
DPPIV/CD26 levels and declines in viral loads following 
ART initiation in children using Spearman's correlational 
analysis which was statistically significant  showing that 
this inverse proportionality relationship is significant 
(p= 0.0246) (Figure 1c). The correlation between 
DPPIV/CD26 increase and the CD4+ cell counts increase 
using the same  Spearman’s correlational coefficient was 
however not significant with a (p =0.2236) (Figure 1d). 
This showed that DPPIV/CD26 levels in HIV infected 
children before and after the initiation of ART was 
 Maina et al, Afr. J. Pharmacol. Ther. 2016. 5(4): 263-271 
 
 
A KeSoBAP Publication ©2016. All rights reserved.  ISSN 2303-9841 
267 
inversely proportional to the viral load levels but directly 
proportional to the CD4+ T cell counts, corresponding to 
what we had previously hypothesized. (Songok et al, 
2010; Ohtsuki et al, 2000). Table 1 showing the average 
DPPIV/CD26, viral load levels and CD4+ Cell counts in 
the various age specific groups before and after ARV use. 
Influence of sex and age on DPPIV/CD26 levels in HIV 
infected children on ART  
Next we sought to determine if sex and age of HIV 
positive children, prior to and following initiation of ART 
influenced the levels of DPPIV/CD26. Here we compared 
the levels of DPPIV/CD 26, viral loads, CD 4+ cell counts 
between groups of children categorized based on age 
and gender.  
The levels of DPPIV/CD26 in male study participants 
rose significantly from a mean of 851800 ± 485500 
pg/ml before ART, to  1015000 ± 663000 pg/ml after 
ART (p=0.0112), and similarly in female the same rose 
from 813700 ± 480500 pg/ml before ART to 938700 ± 
605500 pg/ml after ART  (p=0.0526) .When we 
compared the change in DPPIV levels in male vs female 
children before and after ART using the Mann-Whitney 
test we found that p=0.7460 which is not statistically 
significant therefore there is no significant change in 
DPPIV/CD26 with gender. 
  
a) The DPPIV/CD26 levels (pg/ml) as quantified using ELISA while HIV viral loads were quantified using RT-PCR, before and after 
initiation of ART in HIV infected children compared to viral load levels (copies/ml).  
b) The DPPIV/CD26 levels (log pg/ml) compared to the CD4+ Cell counts (log cells/mm3) before and after the use of ARVs. The changes 
in DPPIV/CD26 levels, HIV viral loads and CD4+ cell counts (before and after ART) were statistically analyzed using paired t-test. 
Error bars represent standard error of mean (S.E.M), and * represents p < 0.05, ** p <0.01 and *** is p <0.001. 
 c and d) Spearman’s correlational analysis of DPPIV/CD26 levels and HIV viral loads or CD4+ T cell counts. Spearman’s coefficient R2 
indicates the strength of associations and p-values represent the significance of the associations. 
Figure 1. DPPIV/CD26 in relation to viral load and CD4+ cell counts. 
 
 Maina et al, Afr. J. Pharmacol. Ther. 2016. 5(4): 263-271 
 
 
A KeSoBAP Publication ©2016. All rights reserved.  ISSN 2303-9841 
268 
Table 1: The average DPPIV/CD26, viral load and CD 4+ Cell counts in adolescents, children of ages 3-9 and in infants. 
 
CD26 before 
ART in pg/ml 
CD26 after 
ART in 
pg/ml 
Viral load 
before ART 
in copies 
per ml 
Viral load 
after ART in 
copies per 
ml 
CD4+ cell 
count before 
ART in cells 
per mm3 
CD4+ cell 
counts after 
ART in cells 
per mm3 
Adolescents 10-20 
years 
949733.3 1005333 101108.7 27133.73 399.7 529.9 
Children 3-9 years 
740757.6 933333.3 218446.6 7364.061 587.45 994.42 
Infants below 2 
years of age 
784615.4 998076.9 174246.7 100604 1467.85 1887.46 
Table 1 shows the general mean increases in DPPIV/CD26 before and after ARVs across the age-groups, the reduction in mean levels of 
the viral load copy numbers and the increase in CD 4+ cell counts before and after the use of ARVs across the different age groups. 
 
The viral load levels dropped significantly in the male 
study participants from a mean range of 163600 ± 
205740 copies/ ml before ART, to a mean of 35900 ± 
10610 copies/ml after ART (p=0.0031).  In female study 
participants, the viral load levels declined significantly 
from a mean range of 165400 ± 140210 copies/ml before 
ART to a mean range of 27250 ± 8497 copies/ml after 
ART (p=0.0007). There were no difference in HIV viral 
load between the male and the female children before 
and after ART (Mann-Whitney p=0.9875). 
The CD4+ T cell counts before and after ART in male 
children increased from a mean range of 665.2 ± 694.2 
cells/mm3 before ART to a mean range of 952.9 ± 923 
cells/mm3 after ART (p=0.0021) .In female children, the 
CD4+ T cell counts rose significantly from a mean range 
of 662.9 ± 520.5 cells/mm3 before ART to a mean of 
972.7 ± 765.7 cells/mm3 after ART (p<0.0001) .When the 
change in CD 4+ cell counts before and after ART in males 
was compared to the change in CD 4+ cell counts after 
ART in females by Mann-Whitney test, the p was 0.548 
which is statistically insignificant therefore there is no 
difference in CD 4 + cell counts based on gender. 
In children below 2 years of age, DPPIV/CD26 levels 
before (Mean= 784615.4 ± 200000 pg/ml) and after 
(mean= 998076.9 ± 520000 pg/ml) ART, remained 
unchanged (p=0.15). However, in children between ages 
of 3-9 years, DPPIV/CD26 levels increased significantly 
from a mean range of 740800 ± 340000 pg/ml before 
ART to a mean of 933300 ± 450000 pg/ml after ART 
(p=0.0014). But in adolescents between the ages of 10-
20, DPPIV/CD26 levels remained the same even after 
initiation of ART (mean=949700 ± 705000 pg/ml to 
1005000±805000 pg/ml, p=0.4466). When we 
compared the change in DPPIV/CD26 levels in children 
below 2 years of age to children between the ages of 3-9 
before ART using Mann-Whitney test, p<0.0001 which is 
statistically significant indicating that there is a 
difference in DPPIV/CD 26 between these 2 age groups 
before ART. When we compared the change in DPPIV/CD 
26 after ART between the children below 2 years of age 
to those between ages 3-9,p<0.0001 which is statistically 
significant indicating a difference in DPPIV/CD 26 
between the children of below 2 years to those between 
3-9 years  after ART. When the same was done between 
children below 2 years to adolescents between ages 10-
20, p<0.0001 before ART and p<0.0004 after ART which 
are both statistically significant showing that there is a 
difference between DPPIV/CD 26 between these two age 
groups before and after ART respectively. Finally, the 
change in DPPIV/CD 26 in children of ages 3-9 was 
compared to the change in DPPIV/CD 26 in ages 10-20 
before and after ART using Mann-Whitney test giving a p 
value of 0.2205 before ART and p of 0.581 after ART 
indicating that there is no statistically significant 
difference in DPPIV/CD 26 between ages 3-9 and ages 
10-20 before and after ART respectively. 
Viral load levels in infants remained unchanged, with a 
mean range of 174246.7 ± 380187 copies/ml before ART 
and 100604±144840.5 copies/ml after ART (p=0.37). 
However, in children between ages 3-9, viral load levels 
decreased significantly after ART initiation from a mean 
range of 218400 ± 245220 copies/ml before ART to a 
mean of 7364 ±1331 copies/ml ARVs (p<0.0001). 
Similarly, the viral load levels in adolescents declined 
significantly from a mean of 101100 ± 73891 copies/ml 
before ART to a mean of 27130 ± 23913 copies/ml after 
initiation of ART (p=0.04)  When we compared the 
change in viral load levels before ART between the 
children of ages 2 and below to those of ages 3-9 using 
Mann-Whitney statistics, p<0.0001 which is statistically 
significant indicating that there is a difference in viral 
load levels between children below 2 years of age and 
those between ages 3-9 before or without ART. When we 
compared the change in viral load levels after ART 
between the children of ages 2 and below to those of ages 
3-9 using Mann-Whitney statistics, p=0.0006 which is 
statistically significant indicating that there is a 
difference in viral load levels between children below 2 
years of age and those between ages 3-9 after or with 
ART. When the change in viral load levels before and 
after ART was compared between children below 2 years 
of age to those between ages 10-20 using Mann-Whitney 
test respectively, p was 0.0003 before ART and p=0.001 
after ART which are both statistically significant 
indicating that there is a significant change in viral load 
levels between children of below 2 years and those 
between 10-20 before and after ART respectively. When 
the change in viral load levels before and after ART was 
compared respectively between the children of ages 3-9 
to those between ages of 10-20 using Mann-Whitney test, 
p was 0.0002 before ART and p=0.4303 after ART 
indicating that there is a significant difference in viral 
load levels between children of ages 3-9 to those 
between 10-20 before or without ART but there is no 
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significant difference in viral load levels between these 
two age groups after ART.   
The CD4+ T cell counts remained unchanged in infants 
below 2 years of age with a mean range of 1467.85 ± 
1531 cells/ mm3 before ART to 1887.46±1141 cells/mm3 
after ART (p=0.052). In ages 3-9 the CD4+ T Cell counts 
increased significantly from a mean range of 472.7 ± 364 
cells/mm3 before ART to a mean range of 985.9 ± 570 
cells/mm3 after ART (p<0001). In adolescents between 
ages of 10-20, the CD4+ T cell counts also increased from 
a mean of 399.7 ± 240 cells/mm3 before ART to a mean 
of 529.9 ± 418 cells/mm3 after ART (p=0.0128) .When 
the change in CD 4+ cell counts before ART was 
compared in children below 2 years to children of ages 
3-9 using Mann-Whitney test, p was 0.0058 which is 
statistically significant indicating that there is a 
difference in CD 4+ cell counts between these two age 
groups before or without ART. When the change in CD 4+ 
cell counts after ART was compared in children below 2 
years to children of ages 3-9 using Mann-Whitney test, p 
was 0.0112 which is statistically significant indicating 
that there is a difference in CD 4+ cell counts between 
these two age groups after or with ART. When the change 
in CD 4 + cell counts before and after ART was compared 
respectively between ages of 2 and below to ages 10-20 
years using Mann-Whitney test, p was 0.0509 before or 
without ART and p=0.1458 after or with ART showing 
that there is a statistically insignificant difference in CD 4 
+ cell counts between study participants of ages 2 and 
below to the ones of ages 10 and 20 before or without 
ART and after or with ART respectively. Finally, the 
change in CD 4 + cell counts before and after ART was 
compared respectively between ages 3-9 and ages 10-20 
using Mann-Whitney test giving a p value of 0.0778 
before ART and a p<0.0001 after ART which shows that 
there is a statistically insignificant difference in CD 4+ 
cell counts between ages 3-9 to ages 10-20 before ART 
compared to a statistically significant difference in the 
same age groups after ART. 
4. Discussion 
DPPIV/CD26 is an ectoenzyme that cleaves penultimate 
proline or alanine residues from the N-terminal of 
dipeptides or polypeptides. DPPIV/CD26 exists either in 
a membrane bound or soluble isoform, the latter 
circulates in the peripheral blood (Ohnuma et al, 2008). 
DPPIV/CD26 has been associated with costimulatory 
functions in T-cells associated with its ability to bind to 
adenosine deaminase or CD45 leading to the T-cell 
activation (Ohtsuki et al, 2000; Boonacker et al, 2003; 
Herrera et al,2001).  Previously, we observed a higher 
expression of DPPIV/CD26   in the blood of female sex 
workers who are highly exposed but persistently are HIV 
sero-negative (HESN) (Songok et al, 2010). Based on 
these earlier observations, in this study we sought to 
evaluate if plasma levels of DPPIV/CD26 in HIV infected 
children and young adults, could be used a surrogate 
marker for disease progression 
The present study, demonstrated for the first time that 
the levels of DPPIV/CD26 in HIV infected children and 
young adults, was inversely proportional to HIV viral 
load but directly proportional to CD4+ T cells counts. In 
multiple instances, DPPIV/CD26 levels, HIV viral loads or 
CD4+ T cell counts were dependent on ART but 
independent of gender. The levels of DPPIV expressed 
tended to increase between the ages 0-20 years, 
plateauing at between 10-20 years. Anti-retroviral 
therapy caused significant declines in DPPIV/CD26 
levels in males but not females. Often, the levels of 
DPPIV/CD26 remained unaffected by ART. The 
exception was in children aged 3-9 years, who had higher 
levels of DPPIV/CD26 following ART initiation.  Based on 
the same age stratification, the HIV viral load levels were 
highest in children between 3-9 years of age prior to ART 
compared to those below 2 years or those between 10-
20 years of age. ART effectively reduced the HIV viral 
load in children between 3-9 years and in young adult 
between10-20 years, but failed to do the same in 
children below 2 years of age. Similarly, ART improved 
the CD4+ T cell counts in children (3-9 years) and young 
adults (10-20 years), but failed to do so in children below 
2 years (Ohtsuki et al, 2000).   
The key finding of this study was that DPPIV/CD26 levels 
corresponded to those of CD4+ T cell counts and 
inversely to HIV viral load, suggesting that DPPIV/CD26 
has the potential for use as a marker to predict HIV 
disease progression. The immunological importance is 
not yet clear at this point. However, evidence from 
studies conducted by others suggest that dysregulation 
of the immune system heightens the expression of 
DPPIV/CD26. For instance, its levels are elevated in the 
serum of individuals with metastatic colorectal 
carcinoma and malignancy in papillary carcinoma of the 
thyroid gland compared to healthy subjects (de la Haba-
Rodríguez et al, 2002; Aso et al, 2012). Elevated 
DPPIV/CD26 levels in serum of individuals with type 2 
diabetes produced poor responses to sitagliptin 
treatment (Bunupuradah et al, 2006). This finding also 
corresponds with results from a cohort study showing 
that Highly Exposed but Uninfected commercial sex 
workers in Nairobi had highly elevated DPPIV/CD26 
levels, with these women having low levels of the virus 
showing that DPPIV/CD 26 could have some protective 
properties against the virus as depicted by these sex 
workers who do not seroconvert (Songok et al, 2010). 
Our findings also suggest that the administration of ART 
to HIV-treatment naïve patients boosted the levels of 
DPPIV/CD 26 after ART. In a study conducted in patients 
with primary billiary cirrhosis, levels of DPPIV positive 
peripheral blood lymphocytes were boosted to the range 
observed in healthy subjects in addition to improving the 
liver function parameters of the subjects after the 
administration of ursodeoxycholic acid treatment (Adler 
et al, 1993).  
An outstanding observation from this study was the poor 
response to ART in children below 2 years of age, based 
on changes in CD4+ T cell counts, decline in HIV viral 
loads and likewise DPPIV/CD 26. This could be 
attributed to toxicity of most ARVs and the limited dosing 
alternatives; where very few are available in suspension 
form. This often forces caregivers to decrease the 
duration of the administration of the drugs or reduce 
dosages administered (Natella and Ryan, 2012).Despite 
the presence of liquid formulations, challenges still exist 
in the administered form of the drugs with most still 
existing in tablet form hence posing a challenge in 
swallowing of the drugs in this age group (Bunupuradah 
et al, 2006; Heald et al, 1998). The immune systems of 
children in this age group are still developing therefore 
majority may not demonstrate immunological 
confidence and viral control with the organ systems still 
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immature posing a challenge in absorption and 
metabolism of the drugs (Fukushima et al, 2009; Neely 
and Rakhmanina, 2011). 
5. Conclusion 
This study provided a strong rationale for further 
evaluation of the potential   for use of DPPIV/CD26 as 
marker for ART treatment efficacy in children and young 
adults. This is based on the observation that DPPIV levels 
directly corresponded with CD4+ T cell counts but 
inversely correlated with HIV loads in children with ART 
use. Therefore, demonstrating the potential for use of 
DPPIV/CD 26 in developing diagnostic kits for ART 
monitoring and probably be used in future in the 
development of vaccine initiatives against the virus.  
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